Enhanced vaccine efficacy using mRNA-LNP adjuvants

Researchers at Stanford have developed a novel strategy to enhance vaccine efficacy using mRNA lipid nanoparticles (LNPs) encoding immunostimulatory cytokines. Traditional vaccines can elicit inconsistent immune responses across individuals, particularly in vulnerable populations such as the elderly. This variability often leads to inadequate protection against infectious diseases, necessitating the development of effective adjuvants.

Utilizing an in-house microfluidics system, Stanford scientists produced non-antigen coding mRNA LNPs and evaluated their performance in mice immunized with inactivated influenza vaccine (IIV). The incorporation of mRNA LNPs encoding immunostimulatory cytokines significantly improved antibody induction against both in-vaccine and out-of-vaccine strains. This innovative platform not only enhances the quantity of antibodies produced but also broadens the immune response, providing a robust defense against diverse influenza strains.

The findings indicate that mRNA LNPs can serve as programmable adjuvants, capable of delivering specific cytokine signals to modulate immune responses effectively. This technology presents a promising strategy for improving vaccine responses, particularly in populations with diminished immune function, such as the elderly or immunocompromised individuals.